ClinicalTrials.gg

Program

Ezetimibe

Also written as “ezetimibe”, “ezetimibe (+) simvastatin” and “MK0653, ezetimibe”.

Its studies are mostly in Hypercholesterolemia · Hypertension · Hyperlipidemias · Lipid Metabolism, Inborn Errors · Atherosclerosis, led by 16 companies.

Furthest: phase 4, since Sep 7, 200597 company-led studies, 3 open or runningNext primary completion: Jun 1, 2028 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Organon710 open or runningphase 4since Sep 7, 2005Sep 23, 2004none ahead
Daiichi Sankyo61 open or runningphase 4since Sep 9, 2005Sep 9, 2005Jun 1, 2028phase 3 · NCT07474649
Yuhan40 open or runningphase 4since Jul 12, 2017Jul 12, 2017none ahead
IlDong Pharmaceutical20 open or runningphase 3since Sep 25, 2014Sep 25, 2014none ahead
JW Pharmaceutical21 open or runningphase 4since Feb 18, 2026Oct 6, 2020none ahead
Novartis20 open or runningphase 4since Oct 10, 2006Sep 12, 2005none ahead
Celltrion10 open or runningphase 3since Apr 27, 2026Apr 27, 2026none ahead
Daewon Pharmaceutical10 open or runningphase 3since Jul 24, 2023Jul 24, 2023none ahead
GlaxoSmithKline10 open or runningphase 1since Mar 22, 2012Mar 22, 2012none ahead
Hanlim Pharm.10 open or runningphase 3since Dec 2, 2020Dec 2, 2020none ahead
Hanmi Pharmaceutical10 open or runningphase 1since Apr 29, 2014Apr 29, 2014none ahead
HK inno.N10 open or runningphase 4since Nov 20, 2018Nov 20, 2018none ahead
hyundai-pharm11 open or runningphase 3since Oct 15, 2024Oct 15, 2024none ahead
Merck10 open or runningphase 4since Sep 16, 2008Sep 16, 2008none ahead
NVP Healthcare10 open or runningphase 1since Nov 9, 2014Nov 9, 2014none ahead
Shin Poong Pharmaceutical10 open or runningphase 3since Aug 18, 2017Aug 18, 2017none ahead

Also a collaborator on its studies: pharma-medica-research-inc, Regeneron Pharmaceuticals, merck-frosst-canada-ltd, linical-korea and medpace-inc.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 40 studies since Mar 31, 2008.

  1. Nov 20, 2018HK inno.N's first study: phase 4 study in HypertensionNew to HK inno.NHK inno.N · NCT03847506 · 127 enrolled · Korea, Republic of
  2. Mar 6, 20195 phase 3 studiesOrganon · NCT03884452, NCT03867110, NCT03882996 and 2 more
  3. Mar 11, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT03872232 · 180 enrolled · Korea, Republic of
  4. Aug 8, 2019Phase 4 study in Acute Coronary SyndromeYuhan · NCT04056169 · 50 enrolled · Korea, Republic of
  5. Nov 7, 2019Phase 3 study in HypercholesterolemiaYuhan · NCT04158076 · 131 enrolled · Korea, Republic of
  6. Oct 6, 2020JW Pharmaceutical's first study: phase 3 study in Primary HypercholesterolemiaNew to JW PharmaceuticalJW Pharmaceutical · NCT04584736 · 283 enrolled · Korea, Republic of
  7. Dec 2, 2020Hanlim Pharm.'s first study: phase 3 study in HypertensionNew to Hanlim Pharm.Hanlim Pharm. · NCT04659070 · 156 enrolled · Korea, Republic of
  8. Jul 24, 2023Daewon Pharmaceutical's first study: phase 3 study in HypercholesterolemiaNew to Daewon PharmaceuticalDaewon Pharmaceutical · NCT05970679 · 252 enrolled · Korea, Republic of
  9. Oct 15, 2024hyundai-pharm's first study: phase 3 study in HypertensionNew to hyundai-pharmhyundai-pharm · NCT06646354 · 125 planned · Korea, Republic of
  10. Sep 11, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07182383, NCT07201545
  11. Nov 14, 20252 phase 1 studies in Healthy SubjectsDaiichi Sankyo · NCT07235189, NCT07268625
  12. Feb 18, 2026Phase 4 study in HypercholesterolemiaJW Pharmaceutical · NCT07442630 · 88 enrolled · South Korea
  13. Mar 11, 2026Phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649 · 103 planned · Germany, Italy, Spain
  14. Apr 27, 2026Celltrion's first study: phase 3 study in HypertensionNew to CelltrionCelltrion · NCT07564726 · 163 enrolled · South Korea

Ahead

  1. Jun 1, 2028Primary completion: phase 3 study in Coronary Artery DiseaseDaiichi Sankyo · NCT07474649

TargetBeta

NPC1L1 →read by rule
“Niemann-Pick C1-like protein 1 inhibitor”ChEMBL 37, by rule

Studies

The newest 60 of 97 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07564726Hypertension · South Korea3CompletedCelltrionFeb 13, 2024163
NCT07474649Coronary Artery Disease · Germany, Italy, Spain3Not yet recruitingDaiichi SankyoJun 1, 2028103
NCT07442630Hypercholesterolemia · South Korea4Active, not recruitingJW PharmaceuticalJan 22, 202688
NCT07268625Healthy Subjects · Portugal1CompletedDaiichi SankyoFeb 24, 202658
NCT07235189Healthy Subjects · Portugal1CompletedDaiichi SankyoJan 28, 202658
NCT07201545Healthy Subjects · Portugal1CompletedDaiichi SankyoDec 10, 202558
NCT07182383Healthy Subjects · Portugal1CompletedDaiichi SankyoNov 24, 202558
NCT06646354Hypertension · Korea, Republic of3By invitationhyundai-pharmMay 19, 2025125
NCT05970679Hypercholesterolemia · Korea, Republic of3CompletedDaewon PharmaceuticalApr 13, 2023252
NCT04659070Hypertension · Korea, Republic of3UNKNOWNHanlim Pharm.May 19, 2022156
NCT04584736Primary Hypercholesterolemia · Korea, Republic of3CompletedJW PharmaceuticalJul 16, 2020283
NCT04158076Hypercholesterolemia · Korea, Republic of3CompletedYuhanJan 14, 2021131
NCT04056169Acute Coronary Syndrome · Korea, Republic of4CompletedYuhanJul 23, 201950
NCT03882996Hypercholesterolemia3CompletedOrganonFeb 4, 2003432
NCT03882905Primary Hypercholesterolemia3CompletedOrganonJul 27, 2001769
NCT03882892Hypercholesterolemia3CompletedOrganonAug 8, 2002400
NCT03872232Hypercholesterolemia · Korea, Republic of3CompletedYuhanAug 12, 2020180
NCT03884452Hyperlipoproteinemia Type II3CompletedOrganonMay 24, 200150
NCT03867110Hypercholesterolemia3CompletedOrganonJul 27, 2001628
NCT03847506Hypertension · Korea, Republic of4CompletedHK inno.NDec 2, 2020127
NCT03288038Hypercholesterolemia · Korea, Republic of3CompletedShin Poong PharmaceuticalNov 19, 2015382
NCT03217409Diabetes Mellitus · Korea, Republic of4CompletedYuhanApr 3, 201985
NCT02748057Hypercholesterolemia3CompletedOrganonDec 11, 2017135
NCT02749994Hypercholesterolemia · Korea, Republic of3CompletedIlDong PharmaceuticalFeb 2017396
NCT02741245Hypercholesterolemia3CompletedOrganonJan 18, 2017321
NCT02550288Hypercholesterolemia3CompletedOrganonMay 30, 2016309
NCT02460159Hypercholesterolemia3CompletedOrganonDec 22, 2016135
NCT02289430Healthy1CompletedNVP HealthcareFeb 201559
NCT02251847Hypercholesterolemia · Korea, Republic of3UNKNOWNIlDong PharmaceuticalJul 2015400
NCT02127320Healthy · Korea, Republic of1CompletedHanmi PharmaceuticalSep 201424
NCT01611883Hypercholesterolemia4CompletedOrganonJan 16, 2014152
NCT01597700Hypercholesterolemia · India1CompletedGlaxoSmithKlineJan 30, 201252
NCT01370603Hypercholesterolemia3CompletedOrganonMay 2012328
NCT01370590Hypercholesterolemia3CompletedOrganonApr 2012406
NCT01154036Hypercholesterolemia3CompletedOrganonSep 20121,547
NCT00871351Primary Hypercholesterolemia4CompletedOrganonMay 1, 2010125
NCT00867165Primary Hypercholesterolemia3CompletedOrganonApr 13, 2012138
NCT00862251Cardiovascular Diseases3CompletedOrganonMar 2011808
NCT00753883Hyperlipidemias4CompletedMerckMay 200840
NCT00654628Hypercholesterolemia4CompletedOrganonJul 1, 2009173
NCT00654095Hypercholesterolemia3CompletedOrganonJun 1, 2009146
NCT00653835Hypercholesterolemia4CompletedOrganonAug 1, 2004153
NCT00653796Hypercholesterolemia4CompletedOrganonAug 1, 2004148
NCT00653523Hypercholesterolemia3CompletedOrganonJun 1, 2009151
NCT00653276Cholesterol1CompletedOrganonJan 200413
NCT00652847Hypercholesterolemia4CompletedOrganonMay 20071,140
NCT00652717Cardiovascular Diseases4CompletedOrganonFeb 15, 2005280
NCT00653913Hypercholesterolemia1CompletedOrganonSep 200418
NCT00652444Hypercholesterolemia4CompletedOrganonAug 2004120
NCT00652327Hypercholesterolemia4CompletedOrganonJul 200783
NCT00652301Cholesterol3CompletedOrganonApr 200440
NCT00651963Lipid Metabolism Disorders4CompletedOrganonMar 200580
NCT00651560Hyperlipidemias3CompletedOrganonDec 23, 2005167
NCT00651404Hypercholesterolemia3CompletedOrganonDec 2004137
NCT00651391Hypercholesterolemia3TerminatedOrganonSep 1, 200428
NCT00651274Atherosclerosis4CompletedOrganonAug 1, 2004144
NCT00651144Hypercholesterolemia1CompletedOrganonMay 200340
NCT00651014Hypercholesterolemia4TerminatedOrganonJun 200682
NCT00650819Hypercholesterolemia3CompletedOrganonFeb 1, 2005240
NCT00650689Hypercholesterolemia3CompletedOrganonDec 2004122

How it is read

Names in the registry

  • “Ezetimibe”, 31 entries
  • “ezetimibe”, 11 entries
  • “ezetimibe (+) simvastatin”, 10 entries
  • “MK0653, ezetimibe”, 7 entries
  • “CKD-828, D097, D337”, 6 entries

Codes read as this program: MK0653.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.